This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Metacrine Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dave Maggio

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 06

Equillium acquires Metacrine to extend cash runway through 2024

Equillium (NASDAQ:EQ) announced Tuesday the definitive deal to acquire Metacrine (NASDAQ:MTCR) in an all-stock transaction. The acquisition is estimated to add $33M in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. Net of cash, Equillium will issue stock valued at a 25% premium that is expected to amount to ~$26M. The price range set for stock issue is $2.70 to $4.50. Based in San Diego, California, Metacrine is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat gastrointestinal and liver diseases. It has developed a proprietary farnesoid X receptor platform, including lead molecule MET642, an orally delivered FXR agonist that is claimed to be a potential first-in-class, non-immunosuppressive treatment for inflammatory bowel disease. “The acquisition of Metacrine meaningfully strengthens Equillium’s cash position,” said Bruce Steel, chief executive officer at Equillium. “As we continue to execute on our ongoing clinical development programs this cash runway extension is expected to see us through multiple data catalysts and operational milestones, including our interim data readout from the Type B portion of the EQUALISE study in lupus nephritis patients in the coming weeks followed by topline data in 2023...." Closing of the transaction is expected late 2022 pending approval from both Equillium and Metacrine shareholders. MTCR stock is up 13% in after-hours trading on Tuesday; EQ shares are up 3%. See more healthcare news here.

Analiz Makalesi • Dec 16

What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?

Every investor in Metacrine, Inc. ( NASDAQ:MTCR ) should be aware of the most powerful shareholder groups. Insiders...

CEO

Dave Maggio (64 yo)

less than a year

Görev süresi

Mr. David M. Maggio, also known as Dave, serves as President and Secretary of Otonomy, Inc. since March 31, 2023. He serves as Chief Business Officer, President, Chief Executive Officer, Secretary, Treasur...

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/06/22 00:27
Gün Sonu Hisse Fiyatı	2023/06/20 00:00
Kazançlar	2022/09/30
Yıllık Kazançlar	2021/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Metacrine, Inc. 6 Bu analistlerden , raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Nash	Canaccord Genuity
Joshua Schimmer	Evercore ISI
Antonio Arce	H.C. Wainwright & Co.

This company listing is no longer active

Metacrine Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Metacrine, Inc. Appoints Michael York as Chief Executive Officer

Metacrine, Inc., Annual General Meeting, May 18, 2022

Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

Metacrine, Inc. Announces Board Changes

Metacrine, Inc. Announces Resignation of Catherine Lee as EVP, General Counsel and Corporate Secretary

Recent updates

Metacrine, Inc.(OTCPK:MTCR) dropped from NASDAQ Composite Index

Metacrine, Inc. Appoints Michael York as Chief Executive Officer

Metacrine Receives the Delisting Notice from Nasdaq

Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. (NasdaqCM:MTCR) from a group of shareholders.

Price target decreased to US$0.50

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium acquires Metacrine to extend cash runway through 2024

Price target decreased to US$1.00

Metacrine, Inc., Annual General Meeting, May 18, 2022

Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

Metacrine, Inc. Announces Board Changes

Metacrine, Inc. Announces Resignation of Catherine Lee as EVP, General Counsel and Corporate Secretary

Price target increased to US$6.17

Metacrine, Inc.(NasdaqGM:MTCR) dropped from Russell Microcap Growth Index

Metacrine, Inc. Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

President recently bought US$75k worth of stock

Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

Metacrine Accelerates MET409 Clinical Development Milestone

Independent Director has left the company

Metacrine, Inc. Provides Interim Data from the Phase 2a Trial of MET642 and Topline Results from a Phase 2a Trial of MET409

Independent Director has left the company

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference

Metacrine, Inc. Initiates Phase 2a Trial of Met642 for the Treatment of Patients with Nash

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

New 90-day high: US$10.82

Metacrine, Inc. Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

Metacrine, Inc. Reports Positive Results from Phase 1 Trial of MET642